Servier is paying $1.8 billion upfront for the oncology assets, with the total value of the deal potentially rising to $2 billion if Agios’ key pipeline candidate vorasidenib – a dual ...

Servier is paying $1.8 billion upfront for the oncology assets, with the total value of the deal potentially rising to $2 billion if Agios’ key pipeline candidate vorasidenib – a dual ...

Under this global agreement, Servier will develop and commercialize BDTX-4933, a small molecule designed by Black Diamond Therapeutics to address unmet medical needs in RAF/RAS-mutant solid tumors.

Servier and Black Diamond Therapeutics (BDTX) announced a strategic worldwide licensing agreement for BDTX-4933, a potential best-in-class ...

The partnership underscores Servier's commitment to developing targeted therapies that address unmet medical needs in oncology Servier will develop and commercialize BDTX-4933, a Phase 1 asset with ...

French independent pharma firm Servier and USA-based Black Diamond Therapeutics (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic ...

Black Diamond said Servier will develop and commercialize BDTX-4933, a small molecule designed by the Cambridge, Mass., company to address unmet medical needs in RAF/RAS-mutant solid tumors.

Under this global agreement, Servier will develop and commercialize BDTX-4933, a small molecule designed by Black Diamond Therapeutics to address unmet medical needs in RAF/RAS-mutant solid tumors.

Servier will lead the development activities and the worldwide commercialization of BDTX-4933 across multiple indications. Currently, in Phase 1 development, BDTX-4933 is designed to target RAS ...

SURESNES, France - Servier, a global pharmaceutical group ... BDTX-4933 is designed to address the unmet medical needs of patients with RAF/RAS-mutant solid tumors. The ongoing Phase 1 clinical ...